The application is supported by data from the phase 3 study that evaluated the efficacy and safety of ravulizumab-cwvz in 175 adults with generalized myasthenia gravis who were not previously treated with a complement inhibitor.
Vyvgart is a neonatal Fc receptor antagonist designed to reduce IgG antibody levels and block the IgG recycling process.
Vyvgart (efgartigimod), a neonatal Fc receptor blocker, was approved to treat generalized myasthenia gravis in adults who test positive for the anti-acetylcholine receptor antibody.
This meta-analysis of studies comparing 2 or more surgical approaches vs thymectomy aimed to identify the best option for myasthenia gravis patients.
A team of researchers assessed the safety, efficacy, and tolerability of efgartigimod for the treatment of patients with generalized myasthenia gravis.
A team of investigators evaluated the relationship between changes in AChR Ab levels induced by immunosuppressive treatment and myasthenia gravis prognosis at 1-year following treatment in patients with the disease.
Efgartigimod may be an effective and well-tolerated treatment option for patients with myasthenia gravis.
Investigators evaluated the characteristics and risk factors for neurologic adverse events associated with immune checkpoint inhibitors.
Investigators assessed the safety and efficacy of tacrolimus monotherapy as an initial approach for patients with drug-naïve myasthenia gravis.
Efgartigimod, an Fc receptor antagonist, reduces disease-causing immunoglobulin G (IgG) antibodies and blocks the IgG recycling process.
